info@businessghana.com
Precision medicine company, Revna Biosciences (RevnaBio) has secured triple accreditation from the American Association for Laboratory Accreditation (A2LA) to help strengthen its laboratory and biobanking capabilities to support clinical diagnostics and biomedical research across Africa.
The accreditation covers three internationally recognised standards: ISO 15189 for medical laboratories, ISO 20387 for biobanking and ISO/IEC 17043 for proficiency testing providers.
According to the company, the combined certification validates the strength of its integrated quality systems across clinical diagnostics, biospecimen management and laboratory performance monitoring.
The Chief Executive and co-founder of the company, Derrick Akpalu said the accreditation reflects the company’s commitment to building laboratory systems that meet global standards while addressing healthcare needs locally.
“By strengthening diagnostic quality, biospecimen infrastructure, and laboratory performance monitoring, we aim to support improved healthcare locally while enabling meaningful collaboration with global research partners working to advance precision medicine,” he said.
He said that the recognition would enable his outfit to deliver reliable molecular testing services for patients while supporting partnerships with pharmaceutical firms, diagnostics developers and research institutions conducting biomedical research on the continent.
He added that the milestone represents an important step in expanding precision medicine infrastructure in West Africa and improving access to internationally accredited diagnostic services.
Through its ISO 15189-accredited laboratory, RevnaBio provides molecular and genomic testing designed to meet global standards for accuracy, quality and traceability.
The company said the capability allows clinicians to make better-informed treatment decisions and helps reduce the need to send diagnostic samples overseas for advanced testing.
It noted that strengthening local diagnostic capacity could contribute to improved healthcare delivery and patient outcomes in Ghana.
RevnaBio’s ISO 20387 accreditation also validates its governance and operational systems for collecting, processing and storing research-grade biospecimens.
The company said the infrastructure enables biological samples to be linked to high-quality clinical and molecular data, supporting research aimed at improving understanding of diseases affecting African populations and people of African descent globally.
According to the firm, expanding biospecimen infrastructure within Africa will help ensure research involving African populations is conducted with stronger scientific standards and ethical oversight.
The ISO/IEC 17043 accreditation authorises RevnaBio to design and deliver accredited proficiency testing programmes that help laboratories measure and improve their performance.
The company said the service would help address the shortage of locally delivered external quality assessment programmes in parts of West Africa.
By providing standardised benchmarking and quality monitoring, RevnaBio aims to support laboratory networks and strengthen diagnostic reliability across healthcare systems in the region.
For her part, the Board member of the company, Jennifer Dent, described the achievement as an important milestone that demonstrates the company’s commitment to quality and scientific excellence.
“I am incredibly proud to see the company achieve this important milestone. Receiving triple accreditation from the American Association for Laboratory Accreditation reflects RevnaBio’s commitment to quality, scientific excellence and global laboratory best practices.
“The triple accreditation reflects the team’s commitment to quality, scientific excellence and global standards,” she emphasised.
She added that the accreditation would strengthen partnerships and support African scientists and clinicians in leading impactful biomedical research.
